155 related articles for article (PubMed ID: 31960455)
1. Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma.
Giuliano A; Dobson J
J Small Anim Pract; 2020 Mar; 61(3):190-194. PubMed ID: 31960455
[TBL] [Abstract][Full Text] [Related]
2. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
3. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
Grant J; North S; Lanore D
J Small Anim Pract; 2016 Jun; 57(6):283-90. PubMed ID: 27136424
[TBL] [Abstract][Full Text] [Related]
4. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.
Brockley LK; Cooper MA; Bennett PF
N Z Vet J; 2013 Jan; 61(1):25-31. PubMed ID: 22913610
[TBL] [Abstract][Full Text] [Related]
5. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
6. Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome.
Tellado MN; Maglietti FH; Michinski SD; Marshall GR; Signori E
Radiol Oncol; 2020 Mar; 54(1):68-78. PubMed ID: 32187017
[TBL] [Abstract][Full Text] [Related]
7. Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.
Igase M; Inanaga S; Nishibori S; Itamoto K; Sunahara H; Nemoto Y; Tani K; Horikirizono H; Nakaichi M; Baba K; Kambayashi S; Okuda M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
J Vet Sci; 2024 Jan; 25(1):e15. PubMed ID: 38311328
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of chemotherapeutic effect without wide-margin surgery or radiation therapy in dogs with oral malignant melanoma.
Xia Y; Liao AT; Lee J
Can Vet J; 2024 Apr; 65(4):343-350. PubMed ID: 38562982
[TBL] [Abstract][Full Text] [Related]
10. Prognosis after surgical excision of canine melanomas.
Bostock DE
Vet Pathol; 1979 Jan; 16(1):32-40. PubMed ID: 462717
[TBL] [Abstract][Full Text] [Related]
11. [Developmental studies on melanoma of the skin and mouth mucosa of dogs].
Frese K
Vet Pathol; 1978 Jul; 15(4):461-73. PubMed ID: 695220
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic studies in a canine malignant melanoma.
Mayr B; Eschborn U; Schleger W; Loupal G; Burtscher H
J Comp Pathol; 1992 Apr; 106(3):319-22. PubMed ID: 1602064
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012).
Kawabe M; Mori T; Ito Y; Murakami M; Sakai H; Yanai T; Maruo K
J Am Vet Med Assoc; 2015 Nov; 247(10):1146-53. PubMed ID: 26517618
[TBL] [Abstract][Full Text] [Related]
14. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision.
Dank G; Rassnick KM; Sokolovsky Y; Garrett LD; Post GS; Kitchell BE; Sellon RK; Kleiter M; Northrup N; Segev G
Vet Comp Oncol; 2014 Mar; 12(1):78-84. PubMed ID: 22737988
[TBL] [Abstract][Full Text] [Related]
15. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.
Manley CA; Leibman NF; Wolchok JD; Rivière IC; Bartido S; Craft DM; Bergman PJ
J Vet Intern Med; 2011; 25(1):94-9. PubMed ID: 21143299
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional retrospective study of canine foot pad malignant melanomas: 20 cases.
Jeon MD; Leeper HJ; Cook MR; McMillan SK; Bennett T; Murray CA; Tripp CD; Curran KM
Vet Comp Oncol; 2022 Dec; 20(4):854-861. PubMed ID: 35771690
[TBL] [Abstract][Full Text] [Related]
18. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
[TBL] [Abstract][Full Text] [Related]
19. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK.
Verganti S; Berlato D; Blackwood L; Amores-Fuster I; Polton GA; Elders R; Doyle R; Taylor A; Murphy S
J Small Anim Pract; 2017 Jan; 58(1):10-16. PubMed ID: 28094857
[TBL] [Abstract][Full Text] [Related]
20. Fascin-1 expression in canine cutaneous and oral melanocytic tumours.
Yamada N; Mori T; Murakami M; Noguchi S; Sakai H; Akao Y; Maruo K
Vet Comp Oncol; 2012 Dec; 10(4):303-11. PubMed ID: 22236355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
